ESR1 and breast carcinoma: Further, our results suggest that methods of targeting AR signaling using pharmacologic AR antagonists and/or blocking androgen production with CYP17 inhibitors are insufficient to alter the radiation response in vitro in AR+/ER+ breast cancer models.